(0)
SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) has reached its pre-specified primary endpoints of Progression Free Survival (PFS) and Overall Survival (OS) at the interim analysis of the randomized, double-blind, placebo-controlled, multi-center, phase III clinical study JUPITER-06 (Clinicaltrials.gov identifier: NCT03829969). Junshi Biosciences will communicate with the regulatory authorities regarding the supplemental New Drug Application (sNDA) in the near future.
Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
CanSinoBIO Receives Approval to Launch Inhaled COVID-19 Vaccine Trial
sputniknews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sputniknews.com Daily Mail and Mail on Sunday newspapers.
China offers its Covid-19 vaccines to diplomats, foreign journalists
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Nearly 65 million COVID-19 vaccine doses had been administered across China by Sunday, Li Bin, deputy head of the National Health Commission, told a press conference in Beijing on Monday.
China has endeavored to steadily increase its vaccinated population, said Li, noting that a total of 15 supervisory groups had been dispatched to provide guidance across the country.
The best way to prevent COVID-19 cases is vaccination, and it is China s current top COVID-19 prevention and control strategy, said Li.
Noting an overall stable COVID-19 situation in China, Li pointed out the potential risks of imported cases and cluster cases in some localities, and called on more people to get vaccinated.